Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 5/20 | 1.00 |
| ▸ | NQO1 | P15559 | 1/20 | 0.57 |
| ▸ | POR | P16435 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | APAF1 | O14727 | 2/20 | 0.52 |
| ▸ | TDP2 | O95551 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | S100A4 | P26447 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9674258 | 0.95 | PTPRC (0.91) | PTPRCNQO1PORMEN1KMT2A | |
| SCHEMBL28782 | 0.86 | PTPRC (0.76) | PTPRCNQO1PORMEN1KMT2A | |
| SCHEMBL29364602 | 0.86 | PTPRC (0.76) | PTPRCNQO1PORMEN1KMT2A | |
| SCHEMBL9672807 | 0.82 | PTPRC (0.69) | PTPRCNQO1PORMEN1KMT2A | |
| SCHEMBL16162323 | 0.78 | PTPRC (0.62) | PTPRCNQO1PORMEN1KMT2A | |
| SCHEMBL12179511 | 0.75 | PTPRC (0.60) | PTPRCNQO1PORMEN1KMT2A | |
| SCHEMBL22730859 | 0.74 | PTPRC (0.58) | PTPRCNQO1PORMEN1KMT2A | |
| SCHEMBL3333300 | 0.73 | DNMT1 (0.62) | PTPRCNQO1PORMEN1KMT2A | |
| 9,10-Phenanthrenequinone SCHEMBL43050 | 0.71 | MEN1 (1.00) | PTPRCMEN1KMT2AMAPTPOLB | |
| 9,10-Phenanthrenequinone SCHEMBL2157215 | 0.71 | MEN1 (1.00) | PTPRCMEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190204340-A1 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-07-04 | — | — | US | claimed |
| WO-2012160563-A2 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-11-29 | — | — | WO | claimed |
| EP-1242086-B1 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | EP | claimed |
| US-20030130298-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | US | claimed |
| EP-1242086-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001045680-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-11852634-B2 | Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-26 | — | — | US | disclosed |
| CN-115803060-A | Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients | (株) 娜迪安生物公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20210041455-A1 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-02-11 | — | — | US | disclosed |
| US-20190204340-A1 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-07-04 | — | — | US | disclosed |
| US-10288622-B2 | Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-05-14 | — | — | US | disclosed |
| EP-3263127-A1 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | Yeda Research and Development Co. Ltd (IL) | 2018-01-03 | — | — | EP | disclosed |
| EP-2715350-B1 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | YEDA RES & DEV (IL) | 2017-09-27 | — | — | EP | disclosed |
| WO-2012160563-A2 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2012-11-29 | — | — | WO | disclosed |
| US-7691418-B2 | Composition for inhibiting or preventing the formation of a biofilm | OYSTERSHELL NV (BE) | 2010-04-06 | — | — | US | disclosed |
| US-20070258913-A1 | Composition for Inhibiting or Preventing the Formation of a Biofilm | OYSTERSHELL NV (BE) | 2007-11-08 | — | — | US | disclosed |
| EP-1242086-B1 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| US-20030130298-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | US | disclosed |
| EP-1242086-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001045680-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258913-A1 | Composition for Inhibiting or Preventing the Formation of a Biofilm | NQO2, NFKBIA, CROCC | PTPRC 4185/4885NQO1 17/4885POR 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.